Influence of interleukin-1β gene polymorphisms on age-at-onset of sporadic Parkinson's disease
Section snippets
Acknowledgements
This work was supported by a Grant-In-Aid for Scientific Research from Ministry of Health and Welfare of Japan.
References (17)
Inflammatory processes and anti- inflammatory drugs in Alzheimer's disease: a current appraisal
Neurobiol. Aging
(1996)- et al.
Oxidative stress and antioxidant therapy in Parkinson's disease
Prog. Neurobiol.
(1996) - et al.
Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist
Gastroenterology
(1994) - et al.
Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients
Neurosci. Lett.
(1994) - et al.
Mitochondrial complex I deficiency in Parkinson's disease
Lancet
(1989) - et al.
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients
Neurosci. Lett.
(1995) - et al.
Criteria for diagnosing Parkinson's disease
Ann. Neurol.
(1992) - et al.
HLA and T-cell receptor gene polymorphisms in Guillain-Barré syndrome
Neurology
(1998)
Cited by (92)
A systematic review and meta-analysis: The effects of probiotic supplementation on metabolic profile in patients with neurological disorders
2020, Complementary Therapies in MedicineGenetic modifiers of age-at-onset in polyglutamine diseases
2018, Ageing Research ReviewsCitation Excerpt :Due to their ubiquitous implication in metabolic processes across neurodegenerative diseases, more variants in mtDNA may eventually be found to be relevant for polyQ-diseases. Interleukin (IL)-1β, a major proinflammatory cytokine, has been associated with AD and PD (Grimaldi et al., 2000; Nishimura et al., 2000). A study in a Japanese SCA6 cohort found that a IL-1β polymorphism in the promoter region, at position 511 (IL-1B-511), significantly affected AO of SCA6 (Nishimura et al., 2001): homozygous carriers of allele 1 (IL-1B-511*1) showed earlier disease onset than those with allele 2 (IL-1B-511*2).
Neuroinflammation as a therapeutic target in neurodegenerative diseases
2017, Disease-Modifying Targets in Neurodegenerative Disorders: Paving the Way for Disease-Modifying TherapiesGene-environment interactions linking air pollution and inflammation in Parkinson's disease
2016, Environmental ResearchAssociation of microtubule associated protein tau/Saitohin (MAPT/STH) MAPT-238bp/STH Q7R polymorphisms and Parkinson's disease: A meta-analysis
2014, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Parkinson’s disease (PD) is a neurodegenerative disorder that is characterized by progressive loss of dopamine neurons in the substantia nigra [1].
Glutathione transferases, regulators of cellular metabolism and physiology
2013, Biochimica et Biophysica Acta - General SubjectsCitation Excerpt :The mechanism by which GSTO1 mediates its effects on these different neurological diseases is currently unclear. However, GSTO1-1 activity has been implicated in the activation of the pro inflammatory cytokine IL1β and since there have been a number of reports indicating an association between IL1β variants and risk of Alzheimer's and Parkinson's disease it is possible that inflammation may play a common role [178–182]. Because it has been difficult to express recombinant GSTO2-2, it has not been as extensively characterized as GSTO1-1.